IL17A and cancer: High or low levels of anti-inflammatory cytokines, such as interleukin-10, in the absence or presence of proinflammatory cytokines, such as interleukin-17, delineate the fate of T cells (regulatory T or T-helper 17 cells), which subsequently affect the progression of cancer [21].